Correspondence

Conflicts of interest in Twitter

We have previously shown that 79.5% of US-based haematologist-oncologists on Twitter have at least one financial conflict of interest (FCOI) with the biopharmaceutical industry. However, we did not study whether conflicted physicians tweet about specific products for which they have a FCOI. Using our list of all US-based haematologist-oncologists on Twitter,1 we focused on the subset about specific products for which they have a FCOI. Using our list of all US-based haematologist-oncologists on Twitter,7 we included disclosures of their payments, and these were in their 5-line twitter biography. When we compared 100 tweets about conflicted drugs with 100 tweets about non-conflicted drugs coded at random, conflicted tweets were more likely to be positive (66 vs 50; p=0.02), similarly likely to be neutral (35 vs 30, p=0.45), and less likely to be negative (4 vs 15; p=0.008). Thus, we found that a majority of physicians on Twitter with significant financial conflict and frequent tweets mention specific drugs for which they have a conflict; and almost none disclose financial ties. Although these physicians also tweet about drugs for which they have no conflict, comparing these rates is a false equivalence. There are 371 biopharmaceutical companies in the world whose products could be discussed, but more than half of drug mentions refer to a median of six companies that pay these physicians. Moreover, doctors are more positive about drugs whose companies pay them.

Our results raise the concern that financial conflict of interest must be considered with the growing use of social media to discuss cancer products and practices,1 as well as policies regarding disclosure, divesture, audit and recusal may be considered.

Victoria Kaestner, Audrey Brown, Derrick Tao, *Vinay Prasad
prasad@ohsu.edu

<table>
<thead>
<tr>
<th>Tweet &amp; FCOI characteristics</th>
<th>Median (range; IQR) unless otherwise stated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of tweets</td>
<td>584 (101–65000; 249–18535)</td>
</tr>
<tr>
<td>Number of accounts following</td>
<td>260 (14–1270; 33–3592)</td>
</tr>
<tr>
<td>Number of followers</td>
<td>6235 (19–43815; 289–14015)</td>
</tr>
<tr>
<td>Total general payments, 2014 (US$)</td>
<td>11368.45 (1031.49–444055.94; 4292.16–332134.47)</td>
</tr>
<tr>
<td>Number of tweets mentioning non-conflicted drug</td>
<td>8 (0–121; 3–18)</td>
</tr>
<tr>
<td>Number of tweets mentioning conflicted drug</td>
<td>7 (0–114; 1–20)</td>
</tr>
<tr>
<td>Number of companies from which they took payments</td>
<td>6 (1–30; 3–10)</td>
</tr>
<tr>
<td>Number of unique non-conflicted drugs mentioned*</td>
<td>4 (0–24; 2–7)</td>
</tr>
<tr>
<td>Number of unique conflicted drugs mentioned*</td>
<td>3 (0–36; 1–5)</td>
</tr>
</tbody>
</table>

Source and disclosures

Range of date joined | 7/22/2007-5/1/2016 |
Number of people who disclosed (%) | 2 (1%) |

Affiliation characteristics

MD Anderson | 12 |
Cleveland Clinic | 8 |
Memorial Sloan Kettering Cancer Center | 8 |
Dana Farber Cancer Institute | 6 |
University of Miami | 5 |
Carolinas Health System | 4 |
Duke | 4 |
Emory | 4 |
Cornell | 3 |
Cancer Treatment Centers of America | 3 |

FCOI-financial conflicts of interest. *All mentions of the same drug were counted only once. †Number of people with those affiliations.

Table: Physician characteristics

| 2252 (52%) regarded conflicted drugs. Only two (1-3%) of the 156 individuals included disclosures of their payments, and these were in their 5-line twitter biography. When we compared 100 tweets about conflicted drugs with 100 tweets about non-conflicted drugs coded at random, conflicted tweets were more likely to be positive (66 vs 50; p=0.02), similarly likely to be neutral (35 vs 30, p=0.45), and less likely to be negative (4 vs 15; p=0.008). Thus, we found that a majority of physicians on Twitter with significant financial conflict and frequent tweets mention specific drugs for which they have a conflict; and almost none disclose financial ties. Although these physicians also tweet about drugs for which they have no conflict, comparing these rates is a false equivalence. There are 371 biopharmaceutical companies in the world whose products could be discussed, but more than half of drug mentions refer to a median of six companies that pay these physicians. Moreover, doctors are more positive about drugs whose companies pay them. Our results raise the concern that financial conflict of interest must be considered with the growing use of social media to discuss cancer products and practices,1 as well as policies regarding disclosure, divesture, audit and recusal may be considered.

For a list of pharmaceutical companies in the USA see https://www.drugs.com/pharmaceutical-companies.html

For the Open Payments website see https://openpaymentsdata.cms.gov
We will briefly explain the biosimilarity from that of traditional innovative biosimilars. This pathway is different from an extensive similarity exercise, which is robust endpoints.

Biolsimilar phase 3 trials did not have these authors argued that the two results were put in perspective in a Comment,3 in their Comment, to the two largest biosimilar trials in oncology.1,2 The problem is not about having a different opinion, and reading and interpreting clinical trial data differently; it is about having a new and different concept of drug development and of how to obtain evidence for similarity. It is important for clinicians to understand the scientific foundations of biosimilar development to appreciate the full potential for access to treatment and for great savings in health-care cost.

Subsequently, for the development of the rituximab biosimilar, clinical trials were done to confirm similarity in safety, PK and PD, and efficacy. First, a rather traditional bioequivalence trial confirmed bioequivalence and second, a phase 3 confirmatory trial showed the molecule did not behave differently from the reference product in patients. The endpoints were selected to be the most sensitive to show up any difference, in case there was one. Therefore, adequate endpoints may differ from innovator trials.4 This research was done on the basic assumption that if the molecules are the same, they should have a similar effect on patients.

Rheumatoid arthritis is the best model for investigating PK and PD, because of the rituximab dosing schedule and the relatively low variability in peripheral blood B-lymphocyte counts. Efficacy in rheumatoid arthritis was assessed with disease activity score. Indication extrapolation is an important feature in biosimilar development.3 In oncology, biosimilar trials have been done in follicular lymphoma, a well defined entity, for which the role of rituximab is undisputable, especially when combined with cyclophosphamide, vincristine, and prednisolone chemotherapy. The response rate chosen as a primary target is fully acceptable to confirm biosimilarity since it constitutes the most sensitive endpoint to compare the different molecules.

In our opinion it is rather disappointing that the special biosimilar development pathway was underexposed in the Comment1 to the two largest biosimilar trials in oncology.1,2 The problem is not about having a different opinion, and reading and interpreting clinical trial data differently; it is about having a new and different concept of drug development and of how to obtain evidence for similarity. It is important for clinicians to understand the scientific foundations of biosimilar development to appreciate the full potential for access to treatment and for great savings in health-care cost.


Research on Biosimilars: pivotal trials and principles

Biopharmaceuticals have been a fundamental part of modern oncology armamentarium. The registration of growth factor biosimilars (EPO and G-CSF) in Europe induced an immediate 30–40% price drop, decreasing the financial burden to health care and increasing access for patients. In 2017 the European Medicines Agency approved two biosimilars for rituximab, a monoclonal antibody essential in B-cell lymphoma therapy. Several biosimilars of other game changing biological drugs such as infliximab, etanercept, and adalimumab have been granted a marketing authorisation, and there are more to come (eg, bevacizumab, trastuzumab). Physicians should therefore get familiar with the principles of biosimilar development, which is fundamentally different from that of testing innovative compounds.

Two pivotal phase 3 trials1,2 for biosimilar rituximab were published in The Lancet Haematology, and the results were put in perspective in a Comment by Shinichi Makita and Kensei Tobinai.3 In their Comment, these authors argued that the two biosimilar phase 3 trials did not have robust endpoints.

These trials were both part of an extensive similarity exercise, which is typical for the development pathway of biosimilars. This pathway is different from that of traditional innovative medicines. In this Correspondence, we will briefly explain the biosimilarity pathway as it has evolved over the past 10 years with great success in the European Union.

Biosimilarity is established in a stepwise approach. The proposed biosimilars are tested in preclinical studies up to beyond doubt as being almost indistinguishable to the originator biological in physicochemical characterisation (eg, primary structure, glycosylation, heterogeneity, post-translational modifications, and purity) and biological characterisation (for rituximab biosimilar: target and receptor binding, apoptosis, complement mediated cytotoxicity, and antibody-dependent cellular toxicity). It is followed by pharmacokinetics (PK) and pharmacodynamics (PD), toxicity, and efficacy studies done on animal models, confirming the similarity.

Subsequently, for the development of the rituximab biosimilar, clinical trials were done to confirm similarity in safety, PK and PD, and efficacy. First, a rather traditional bioequivalence trial confirmed bioequivalence and second, a phase 3 confirmatory trial showed the molecule did not behave differently from the reference product in patients. The endpoints were selected to be the most sensitive to show up any difference, in case there was one. Therefore, adequate endpoints may differ from innovator trials.4 This research was done on the basic assumption that if the molecules are the same, they should have a similar effect on patients.

Rheumatoid arthritis is the best model for investigating PK and PD, because of the rituximab dosing schedule and the relatively low variability in peripheral blood B-lymphocyte counts. Efficacy in rheumatoid arthritis was assessed with disease activity score. Indication extrapolation is an important feature in biosimilar development.3 In oncology, biosimilar trials have been done in follicular lymphoma, a well defined entity, for which the role of rituximab is undisputable, especially when combined with cyclophosphamide, vincristine, and prednisolone chemotherapy. The response rate chosen as a primary target is fully acceptable to confirm biosimilarity since it constitutes the most sensitive endpoint to compare the different molecules.

In our opinion it is rather disappointing that the special biosimilar development pathway was underexposed in the Comment1 to the two largest biosimilar trials in oncology.1,2 The problem is not about having a different opinion, and reading and interpreting clinical trial data differently; it is about having a new and different concept of drug development and of how to obtain evidence for similarity. It is important for clinicians to understand the scientific foundations of biosimilar development to appreciate the full potential for access to treatment and for great savings in health-care cost.

WJ received research funding and lecture honoraria from Sandoz. AGV has received personal fees from Amgen, Bioenta, Abbevie, Boehringer Ingelheim, Medicines for Europe, Pfizer, Roche, Mundipharma, and Sandoz. JA is an employee of Sandoz and is eligible for stock options. BC has received research funding from Celltrion during the conduct of the cited study. BC has also received personal fees from Celltrion, Roche, Pfizer, Mundipharma, Celgene, MorphoSys, Gilead, Novartis, and Takeda outside the submitted work. WSK declares no competing interests.

*Wojciech Jurczak, Arnold G Vulto, Jutta Amersdorffer, Won S Kim, Bertrand Coiffier
wjurczak@uj.edu.pl

Department of Hematology, Jagiellonian University, 31-501 Krakow, Poland (WJ); Hospital Pharmacy Erasmus MC, Rotterdam, Netherlands (AGV); Hexal, Holzkirchen, Germany (JA); Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (WSK); and Hospices Civils de Lyon, Lyon, France (BC)
